Revisiting the ultimate target of treatment for prostate cancer.
Dahut
William L
WL
Division of Clinical Sciences, National Cancer Institute, Bethesda, MD 20892, USA.
Madan
Ravi A
RA
D000726:Androgen Antagonists / Q000627:therapeutic use*; D001549:Benzamides; D002986:Clinical Trials as Topic; D016503:Drug Delivery Systems; D006801:Humans; D008297:Male; D009570:Nitriles; D010669:Phenylthiohydantoin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000188:drug therapy*
D000726:Androgen Antagonists; D001549:Benzamides; D009570:Nitriles; D010669:Phenylthiohydantoin; C540278:enzalutamide